

#6/508
8/10/01

DOCKET NO. 71550-45753-DIV2

FACSIMILE COVER SHEET**FAX RECEIVED****AUG 10 2001****GROUP 1600**

To: The Assistant Commissioner for Patents
Washington, DC 20231

ATTENTION: **Examiner M. PAK** FAX NO.: 1-703-308-4242
FROM: David G. Conlin
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
Edwards & Anagell
P.O. Box 9169
Boston, MA 02209
Facsimile Numbers: (617) 439-4179 or (617) 439-7748

TOTAL NUMBER OF PAGES: 58, INCLUDING COVER SHEET

Should there be any problems with the transmission of the following documents(s), please contact Louise M. Rappaport at telephone number (617) 439-4444.

RE: INVENTOR: **S. Hinuma, et al.**
SERIAL NO.: **09/461,436**
FILED: **December 14, 1999**
FOR: **G PROTEIN COUPLED RECEPTOR PROTEIN
PRODUCTION, AND USE THEREOF**

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this copy of Submission of "Sequence Listing," Computer Readable Copy, And/or Amendment Pertaining Thereto For Biotechnology Invention Containing Nucleotide And/Or Amino Acid Sequence (with Request to Transfer) is being transmitted via facsimile on the date shown below to Examiner M. Pak.

A copy of this Submission of Sequence Listing was mailed to the U.S. Patent & Trademark Office on May 11, 2001. The return postcard was never received as confirmation of receipt. During a telephone conference on August 7, 2001 with Examiner Pak, he indicated to Mr. Zachariades that something was received on May 15, 2001 but could not confirm at that time that it was the Submission of the Sequence Listing. Applicants are very anxious to learn of the status of the Sequence Listing. It was suggested by Examiner Pak that we fax the document to ensure receipt. Please confirm that this document has been received and made part of the above-referenced file. Applicant does not believe a fee is required. However, if it is determined that the Sequence Listing was not received, please notify us immediately. The Commissioner is thereby authorized to charge any fees

FAX RECEIVED


AUG 10 2001

GROUP 1600

U.S.S.N. 09/461,436
S. Hinuma, et al.
August 9, 2001
Page 2

which may be required, or credit any overpayment, to Deposit Account No. 04-1105. If an additional extension of time is required, please consider this a petition therefore and charge any additional fees which may be required to Deposit Account No. 04-1105. A duplicate copy of this sheet is enclosed.

Date:

August 9, 2001

David G. Conlin
Nicholas Zachariades

BOS2_174738.1

Practitioner's Docket No. 45753-DIV 2**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re application of: **S. Hinuma, et al.**Serial No.: **09/461,436**GROUP: **1646**Filed: **December 14, 1999**EXAMINER: **M. Pak**For: **G PROTEIN COUPLED RECEPTOR PROTEIN
PRODUCTION, AND USE THEREOF****FAX RECEIVED****AUG 10-2001****Box Sequence****Assistant Commissioner for Patents****Washington, D.C. 20231****GROUP 1600****SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE***(check and complete this item, if applicable)*

- 1.
- ☒
- This replies to the Office Letter DATED
- April 27, 2001
- .

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

☒ A copy of the Office Letter is enclosed.**IDENTIFICATION OF PERSON MAKING STATEMENT**

2. I,
- David G. Conlin

*(type or print name of person signing below)***CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))**

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

- ☒ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: May 11, 2001**FACSIMILE**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Louise M. Rappaport
SignatureLouise M. Rappaport

(type or print name of person certifying)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each item as applicable)

- A. ☐ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.
- B. ☐ An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d).
- C. ☐ A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.
- D. ☒ Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Serial No.: 09/038,572

Group No.: 1654

Filed: March 11, 1998

Examiner: Gupta

For: G PROTEIN COUPLED RECEPTOR PROTEIN
PRODUCTION, AND USE THEREOF

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

"Sequence Identifier"

(other application)

(this application)

NOTE. "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. 1.821(e).

E. ☐ A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

☐ Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. § 1.821(b).

F. ☐ Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.

☐ Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

(complete applicable item A and/or B)

A. ☐ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B. ☐ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

☐ a small entity. A statement:

☐ is attached.

☐ was already filed.

☒ other than a small entity.

EXTENSION OF TERM

6.

NOTE: *"Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.*

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

(Submission-Nucleotide and/or Amino Acid Sequence—page 3 of 6)

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable)

- (a) ☐ Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
<input type="checkbox"/> one month	\$110.00	\$ 55.00
<input type="checkbox"/> two months	\$400.00	\$ 200.00
<input type="checkbox"/> three months	\$950.00	\$ 475.00
<input type="checkbox"/> four months	\$1,510.00	\$ 755.00

Fee \$ _____

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

- ☐ An extension for _____ months has already been secured, and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ _____

OR

- (b) ☐ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

8. ☐ Attached is a check in the sum of \$ _____.

- ☐ Charge Account No. _____ the sum of \$ _____.
A duplicate of this transmittal is attached.

FEE DEFICIENCY

9.

NOTE: *If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.*

10. [X] If any additional extension and/or fee is required, charge Account No. 04-1105

SIGNATURE(s)David G. Conlin

(type or print name of person signing statement)



Signature

May 10, 2001
Date

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02109

(If applicable)

Tel. No.: (617) 523-3400
Reg. No. 38,256

- ☐ Inventor
☐ Assignee of complete interest
☐ Person authorized to sign on behalf of assignee
☒ Practitioner of record
☐ Filed under Rule 34(a)
☒ Registration No. 27026
☐ Other

(specify identity of person signing)

(complete the following, if applicable)

Takeda Chemical Industries, Ltd.
(type name of assignee)

1-1, Doshomachi, 4-Chome, Chuo-Ku
Address of assignee

Osaka-She, Osaka 541, JAPAN

Title of person authorized to sign on behalf of assignee


A "STATEMENT UNDER 37 C.F.R. 3.73(b)" is attached.

Assignment recorded in PTO on
Reel 010462 Frame 0285

Reg. No. 27026

Tel. No.: (617) 523-3400

Customer No.:



SIGNATURE OF PRACTITIONER

David G. Conlin
(type or print name of practitioner)

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
Edwards & Angell
P.O. Box 9169
Boston, MA 02209

BOS2_167797.1

Express Mail Label No. TB553893263US
Practitioner's Docket No. 45753-DIV2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): **Suji HINUMA, Yasuaki ITO, Ryo FUJII**

WARNING: 37 CFR 1.41(a)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name or names of the inventor or inventors."

For (title): **G PROTEIN COUPLED RECEPTOR PROTEIN PRODUCTION, AND USE THEREOF**

CERTIFICATION UNDER 37 C.F.R. 1.10¹

(Express Mail label number is mandatory.)

(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date December 14, 1999, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number TB553893263US, addressed to the: Assistant Commissioner for Patents Washington, D.C. 20231.

Donna M. Tommar

(Type or print name of person mailing paper)


Signature of person mailing paper

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,419, at 56,442.

1. Type of Application

This new application is for a(n)

(check one applicable item below)

☐ Original (nonprovisional)

☐ Design

☐ Plant

WARNING: *Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.*

WARNING: *Do not use this transmittal for the filing of a provisional application.*

NOTE: *If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.*

☒ Divisional.

☐ Continuation.

☐ Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)

NOTE: *A nonprovisional application may claim an invention disclosed in one or more prior filed copending nonprovisional applications or copending international applications designating the United States of America. In order for a nonprovisional application to claim the benefit of a prior filed copending nonprovisional application or copending international application designating the United States of America, each prior application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. 112. Each prior application must also be:*

(i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or

(ii) Complete as set forth in § 1.51(b); or

(iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and include the basic filing fee set forth in § 1.16; or

(iv) Entitled to a filing date as set forth in § 1.53(h) and have paid therein the processing and retention fee set forth in § 1.21(l) within the time period set forth in § 1.53(f).

37 CFR 1.78(a)(1).

NOTE: *If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional*

(Application Transmitted — page 2 of 11)

application is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

WARNING: *If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.*

WARNING: *When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional application must be filed prior to the Saturday, Sunday, or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).*

☒ The new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed

A. Required for Filing Date under 37 C.F.R. 1.53(b) (Regular) or 37 C.F.R. 1.153 (Design) Application

270 Pages of Specification
6 Pages of Claims
79 Sheets of Drawing

☒ Formal
☐ Informal

B. Other Papers Enclosed

1 Pages of Abstract
 Other

WARNING: *DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. For comments on proposed changes 37 C.F.R. 1.84, see Notice of March 9, 1988 . . . (1990 O.G. 57-62).*

NOTE: *"Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (5/8 inch) down from the top of the page." 37 C.F.R. 1.84(c).*

(complete the following, if applicable)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. 1.84(b).

4. Additional Papers Enclosed

- ☒ Preliminary Amendment
☒ Information Disclosure Statement (37 C.F.R. 1.98)
☒ Form PTO-1449 (PTO/SB/08A and 08B)
☐ Citations
☐ Declaration of Biological Deposit
☒ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.
☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
☐ Special Comments
☐ Other:

5. Declaration or Oath

NOTE: A newly executed declaration is not required in a continuation or divisional application provided the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47 then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 CFR 1.63(d).

NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name, including the family name, and at least one given name without abbreviation together with any other given name or initial, and the residence, post office address and country of citizenship of each inventor and state whether the inventor is a sole or joint inventor. 37 CFR 1.63(a)(1)-(4).

- ☐ Enclosed

Executed by

(check all applicable boxes)

- ☐ inventor(s).
☐ legal representative of inventor(s). 37 CFR 1.42 or 1.43.
☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.
☐ This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.

- ☒ Not Enclosed.

NOTE: Where the filing is a completion in the U.S. of an International Application, or where the completion of the U.S. application contains subject matter in addition to the International Application, the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL, WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED

- ☒ Application is made by a person authorized under 37 C.F.R. 1.41(c) on behalf of all the above named inventor(s).

(The declaration or oath, along with the surcharge required by 37 CFR 1.16(e), can be filed subsequently).

NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(l).

- ☐ Showing that the filing is authorized.
(not required unless called into question. 37 CFR 1.41(d))

6. Inventorship Statement

WARNING: If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

- ☐ The same.
or
☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,
☐ is submitted.
☐ will be submitted.

7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. An English translation of the non-English language application and the processing fee of \$139.00 required by 37 CFR 1.17(k) is required to be filed with the application, or within such time as may be set by the Office. 37 CFR 1.52(d).

- ☒ English
☐ Non-English

- ☐ The attached translation includes a statement that the translation is accurate. 37 C.F.R. 1.52(d).

8. Assignment

- ☒ An assignment of the invention to Takeda Chemical Industries, Ltd.,
1-1, Doshomachi, 4-chome, Chuo-ku,
Osaka-shi, Osaka 541 Japan
- ☐ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.
- ☐ was filed in the parent application
- ☒ will follow.

NOTE: "If an assignment is submitted with a new application, send two separate letters-one for the application and one for the assignment" Notice of May 4, 1990 (1114 O.G. 77-78).

WARNING: A newly executed "STATEMENT UNDER 37 CFR 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1150 O.G. 62-64.

9. Certified Copy

Certified copy(ies) of application(s)

	<u>Country</u>	<u>Appln. No.</u>	<u>Filed</u>
(1)	Japan	7-074314	March 31, 1995
(2)	Japan	6-189272	August 11, 1994
(3)	Japan	6-189273	August 11, 1994
(4)	Japan	6-189274	August 11, 1994
(5)	Japan	6-236356	September 30, 1994
(6)	Japan	6-236357	September 30, 1994
(7)	Japan	6-270017	November 2, 1994
(8)	Japan	6-326611	December 28, 1994
(9)	Japan	7-007177	January 20, 1995
(10)	Japan	7-057186	March 16, 1995
(11)	Japan	7-093989	April 19, 1995

from which priority is claimed

☒ is enclosed (1).
☒ was filed (2-11).
☐ will follow.

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 C.F.R. 1.16)

A. ☒ Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. 1.16(a) \$760.00
Total Claims (37 CFR 1.16(c))	8	- 20 =	0	x \$ 18.00	
Independent Claims	1	- 3 =	0	x \$73.00	

(37 CFR 1.16(b))

Multiple Dependent
Claim(s), if any
(37 CFR 1.16(d))

+ \$260.00

- ☐ Amendment cancelling extra claims is enclosed.
☐ Amendment deleting multiple-dependencies is enclosed.
☐ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(d).

Filing Fee Calculation \$ 760.00

B. ☐ Design application
 (\$330.00—37 CFR 1.16(f))
 Filing Fee Calculation \$

C. ☐ Plant application
 (\$540.00—37 CFR 1.16(g))
 Filing Fee Calculation \$

11. Small Entity Statement(s)

- ☐ Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is (are) attached.

WARNING: "Status as a small entity must be specifically established in each application or patent in which the status is available and desired. Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. The refiling of an application under § 1.53 as a continuation, division, or continuation-in-part (including a continued prosecution application under § 1.53(f)), or the filing of a reissue application requires a new determination as to continued entitlement to small entity status for the continuing or reissue application. A nonprovisional application claiming benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) of a prior application, or a reissue application may rely on a statement filed in the prior application or in the patent if the nonprovisional application or the reissue application includes a reference to the statement in the prior application or in the patent or includes a copy of the statement in the prior application or in the patent and status as a small entity is still proper and desired. The payment of the small entity basic statutory filing fee will be treated as such a reference for purposes of this section." 37 CFR 1.28(n)(2).

(complete the following, if applicable)

- ☐ Status as a small entity was claimed in prior application _____, filed on _____ from which benefit is being claimed for this application under:

35 U.S.C. § ☐ 119(e),
☐ 120,
☐ 121,

☐ 365(c),

and which status as a small entity is still proper and desired.

☐ A copy of the statement in the prior application is included.

Filing Fee Calculation (50% of A, B or C above) \$_____

NOTE: Any excess of the full fee paid will be refunded if a small entity status is established refund request are filed within 2 months of the date of timely payment of a full fee. The two-month period is not extendable under § 1.136. 37 C.F.R. 1.28(a).

12. Request for International-Type Search (37 C.F.R. 1.104(d))

(complete, if applicable)

☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

13. Fee Payment Being Made at This Time

☒ Not Enclosed

☒ No filing fee is to be paid at this time.
(This and the surcharge required by 37 C.F.R. 1.16(e) can be paid subsequently.)

☐ Enclosed

☐ Filing fee \$_____

☐ Recording assignment
(\$40.00; 37 C.F.R. 1.21(h))
(See attached "COVER SHEET FOR
ASSIGNMENT ACCOMPANYING NEW
APPLICATION.") \$_____

☐ Petition fee for filing by other than
all the inventors or person on behalf
of the inventor where inventor
refused to sign or cannot be reached
(\$130.00; 37 C.F.R. 1.47 and 1.17(i)) \$_____

☐ For processing an application with a
specification in a non-English language
(\$130.00; 37 C.F.R. 1.52(d) and 1.17(k)) \$_____

☐ Processing and retention fee
(\$130.00; 37 C.F.R. 1.53(d) and 1.21(l)) \$_____

☐ Fee for international-type search report
(\$40.00; 37 C.F.R. 1.21(e))

\$ _____

NOTE: 37 CFR 1.21(l) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 CFR 1.53(f) and this, as well as the changes to 37 CFR 1.53 and 1.78(a)(1), indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of § 1.21(l) must be paid, within 1 year from notification under § 53(f).

Total Fees Enclosed

\$ _____

14. Method of Payment of Fees

☐ Check in the amount of \$ _____.

☐ Charge Account No. _____ in the amount of \$ _____.
A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

15. Authorization to Charge Additional Fees

WARNING: If no fees are to be paid on filing, the following items should not be completed.

WARNING: Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

☐ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. _____.

☐ 37 C.F.R. 1.16(a), (f) or (g) (filing fees)

☐ 37 C.F.R. 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or those claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

☐ 37 C.F.R. 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

☐ 37 CFR 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a).

☐ 37 C.F.R. 1.17 (application processing fees)

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. 1.136(a)(3).

☐ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).

NOTE: 37 CFR 1.28(b) requires "Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . issue fee." From the wording of 37 CFR 1.28(b), (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

16. Instructions as to Overpayment

NOTE: "... Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 CFR 1.26(a).

☒ Credit Account No. 04-1105

☐ Refund


SIGNATURE OF PRACTITIONER

Reg. No. 27,026

David G. Conlin
(type or print name of practitioner)

Tel. No.: (617) 523-3400

Dike, Bronstein, Roberts & Cushman, LLP
130 Water Street
P.O. Address

Customer No.: 21874

Boston, MA 02109

☒ **Incorporation by reference of added pages**

(check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)

☒ Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added 5

☒ Plus Added Pages for Papers Referred to in Item 4 Above

Number of pages added 20

☐ Plus added pages deleting names of inventor(s) named on prior application(s) who is/are no longer inventor(s) of the subject matter claimed in this application.

Number of pages added _____

☒ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added 3

☐ **Statement Where No Further Pages Added**

(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)

☐ This transmittal ends with this page.



DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP

INTELLECTUAL PROPERTY LAW

110 WATER STREET
BOSTON, MASSACHUSETTS 02109-4280
TELEPHONE (617) 523-3400
FACSIMILE (617) 523-6440
www.dbrcc.com

MARLBOROUGH, MA OFFICE
TELEPHONE (508) 485-7772

WASHINGTON, D.C. OFFICE
TELEPHONE (703) 553-2563

EMAIL: dgc@dbrcc.com

June 19, 2000
VIA FACSIMILE

Mr. Akinobu Mizuno
Lions Mansion Shibuya Dogenzaka 303
22-12, Maruyama-cho, Shibuya-ku
Tokyo 150-0044, JAPAN

RE: Hinuma, et al.
U.S.S.N. 09/038,572
Your Ref. No.: TK-12US1P
Our Ref. No.: 45753DIV

Dear Mr. Mizuno:

This is just to let you know that I received a telephone call from Examiner Gupta today, indicating that the USPTO records indicated that this case was abandoned because of a failure to respond to an October 1999 request for a sequence listing.

I reviewed the file, and called the Examiner back to point out that on November 15, 1999, we spoke to Examiner Gupta, and pointed out that the sequence listing in this case had already been transferred in November of 1998.

Examiner Gupta has now located the copy of the sequence transfer request we filed in 1998. He said that the case will not be abandoned, but should be getting an office action in due course. We will let you know as soon as we receive that office action.

Best regards,

David G. Conlin

DGC:ms



130 WATER STREET
BOSTON, MASSACHUSETTS 02109-4280
TELEPHONE (617) 523-3400
FACSIMILE (617) 523-6440
www.dbr.com

DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP

INTELLECTUAL PROPERTY LAW

MARLBOROUGH, MA OFFICE
TELEPHONE (508) 485-7772

WASHINGTON, D.C. OFFICE
TELEPHONE (202) 553-2463

EMAIL: jkh@dbrc.com

November 15, 1999

Via Facsimile

Anish Gupta
Patent Examiner
United States Patent and Trademark Office

Re: U.S. Application Serial No. 09/038,572
Filed: March 11, 1998
Our Ref.: 1550-45753-DIV

Dear Examiner Gupta:

Further to our previous fax regarding the above-referenced application, enclosed please find a copy of the return post-card indicating that the Transfer of Sequence Listing was received on March 11, 1998 along with the other papers for filing the Divisional Application.

Please feel free to contact us with any questions, or if we can be of any assistance.

Best regards,

Jennifer K. Holmes
David G. Conklin

JKH/dmt
Enclosures
130989

130 WATER STREET
BOSTON, MASSACHUSETTS 02109-4280
TELEPHONE (617) 523-3400
FACSIMILE (617) 523-6440
www.dbre.com

DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP

INTELLECTUAL PROPERTY LAW

WASHINGTON, D.C.
(703) 553-2563

MARLBOROUGH, MA
(508) 485-7772

FACSIMILE TRANSMITTAL COVER SHEET

DATE: November 15, 1999

TO: Examiner Anish Gupta
(Name)

FAX NO.: 703-305-7401
SPEED DIAL: ()

USPTO
(Company)

COUNTRY: US

FROM: Jennifer K. Holmes

FAX NOS.: (617) 523-6440

Our Reference No.: 1550-45753-DIV

of pages: 3
(including cover)

USSN: 09/038,572

MESSAGE:

Should there be any problem with this transmission, please contact Jennifer K. Holmes at the above telephone number.

NOTICE

The message and/or information which accompanies this facsimile cover sheet is intended for the addressee named above only. If you are not the intended recipient, please contact the sender by collect telephone at the number indicated. You will be advised regarding the disposition of what you have received. The misdelivery of the message and/or information which accompanies this facsimile cover sheet is not intended to be and shall not constitute a disclosure of trade secrets, of attorney work product or of an attorney-client communication. No waiver of any privilege is intended. Thank you for your attention to this matter.

**DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP**

INTELLECTUAL PROPERTY LAW

130 WATER STREET
BOSTON, MASSACHUSETTS 02109-4280
TELEPHONE (617) 523-3400
FACSIMILE (617) 523-6440
www.dbrlc.com

MARLBOROUGH, MA OFFICE
TELEPHONE (508) 485-7772

WASHINGTON, D.C. OFFICE
TELEPHONE (703) 553-2563

EMAIL jkh@dbrc.com

November 15, 1999

Via Facsimile

Anish Gupta
Patent Examiner
United States Patent and Trademark Office

Re: U.S. Application Serial No. 09/038,572
Filed: March 11, 1998
Our Ref.: 1550-45753-DIV

Dear Examiner Gupta:

As per our telephone conversation of earlier today, enclosed please find a copy of the request to transfer the paper and computer readable form of the sequence listing from the parent application (USSN 08/513,974 filed on September 14, 1995) to the above-referenced divisional application (USSN 09/038,572 filed on March 11, 1998). The request was filed on March 11, 1998 concurrently with the filing of the divisional application.

Please feel free to contact us with any questions, or if we can be of any assistance.

Best regards,

Jennifer K. Holmes
David G. Conlin

JKH/dmt
Enclosures
130939

Docket No.: 45753-DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: K. Nakao, et al.

EXAMINER: Not yet assigned

SERIAL NO.: not yet assigned

GROUP:

FILED: herewith

FOR: G PROTEIN COUPLED RECEPTOR PROTEIN, PRODUCTION AND USE THEREOF

Assitant Commissioner for Patents
Washington, D.C. 20231

Sir:


TRANSFER OF SEQUENCE LISTING

The computer readable form in this application is identical with that filed in U.S.S.N. 08/513,974, filed September 14, 1995. In accordance with 37 CFR 1.821(c), please use the computer readable form filed September 16, 1997, in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application.

In accordance with 37 CFR §§1.821-1.825, I hereby state that the content of the paper, computer-readable copies of the sequence listing submitted in accordance with 37 CFR §1.821(c) and (e) on September 16, 1997, respectively, are the same. I hereby state that the submission, filed in accordance with 37 CFR §1.821(g), does not introduce new matter.

Respectfully submitted,

DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP

Date: 11-3-98
David S. Resnick
(Reg. No.: 34235)
Attorney for Applicant
130 Water Street
Boston, Massachusetts 02109
(617) 523-3400

130 WATER STREET
BOSTON, MASSACHUSETTS 02109-4280
TELEPHONE (617) 523-3400
FACSIMILE (617) 523-6440
www.dbr.com

DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP

INTELLECTUAL PROPERTY LAW

WASHINGTON, D.C.
(703) 553-2563

MARLBOROUGH, MA
(508) 485-7772

FACSIMILE TRANSMITTAL COVER SHEET

DATE: November 15, 1999

TO: Examiner Anish Gupta
(Name)

FAX NO.: 703-305-7401
SPEED DIAL. ()

USPTO
(Company)

COUNTRY: US

FROM: Jennifer K. Holmes

FAX NOS.: (617) 523-6440

Our Reference No.: 1550-45753-DIV

of pages: 3
(including cover)

USSN: 09/038,572

MESSAGE:

Should there be any problem with this transmission, please contact Jennifer K. Holmes at the above telephone number.

NOTICE

The message and/or information which accompanies this facsimile cover sheet is intended for the addressee named above only. **If you are not the intended recipient, please contact the sender by collect telephone at the number indicated.** You will be advised regarding the disposition of what you have received. The misdelivery of the message and/or information which accompanies this facsimile cover sheet is not intended to be and shall not constitute a disclosure of trade secrets, of attorney work product or of an attorney-client communication. No waiver of any privilege is intended. Thank you for your attention to this matter.